Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.68 |
| ▸ | CES1 | P23141 | 3/20 | 0.68 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14757895 | 0.84 | CA12 (0.49) | CES2CES1ALDH1A1NPC1RAB9A | |
| SCHEMBL3779540 | 0.84 | CES2 (0.46) | CES2CES1GAAKDM4EMAPT | |
| SCHEMBL30557293 | 0.82 | CPS1 (0.58) | GAAALDH1A1NPC1RAB9A | |
| SCHEMBL20899756 | 0.82 | CPS1 (0.58) | GAAALDH1A1NPC1RAB9A | |
| SCHEMBL9213776 | 0.82 | CYP11B2 (0.51) | CES2CES1CYP11B1CYP11B2GAA | |
| SCHEMBL18281745 | 0.82 | CES2 (0.53) | CES2CES1L3MBTL1GAAALDH1A1 | |
| SCHEMBL29280613 | 0.82 | CES2 (0.44) | CES2CES1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL8070666 | 0.82 | CES2 (1.00) | CES2CES1CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL21987831 | 0.81 | CES2 (0.53) | CES2CES1CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL20659634 | 0.81 | CES2 (0.53) | CES2CES1CYP11B1CYP11B2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1328524-B1 | NOVEL ANTICHOLINERGICS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-12-12 | — | — | EP | disclosed |
| US-7652138-B2 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-01-26 | — | — | US | disclosed |
| US-20050054664-A1 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6852728-B2 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-08 | — | — | US | disclosed |
| EP-1328524-A2 | NOVEL ANTICHOLINERGICS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-07-23 | — | — | EP | disclosed |
| EP-0975584-B1 | SYNTHESIS AND USE OF ALPHA-KETOAMIDE DERIVATIVES AND ARRAYS | ARQULE INC (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6452050-B1 | MONOACYLATION OF SUCH AS 4-AMINOBENZYLAMINE WITH METHYL-2-(2-BENZOTHIENYL)-2-OXOETHANOATE TO PRODUCE POTENTIAL INHIBITORS OF PROTEOLYTIC ENZYMES, PARTICULARLY CYSTEINE PROTEASES | ARQULE, INC. | 2002-09-17 | — | — | US | disclosed |
| US-20020119991-A1 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-08-29 | — | — | US | disclosed |
| WO-2002032898-A2 | NOVEL ANTICHOLINERGICS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-25 | — | — | WO | disclosed |
| US-6143931-A | USEFUL IN DEVELOPING PHARMACEUTIC AGENTS FOR THE TREATMENT OF DISEASES (E.G., CHAGAS' DISEASE) | ARQULE, INC. (US) | 2000-11-07 | — | — | US | disclosed |
| WO-2000053313-A2 | LANTHANIDE CATALYSTS FOR SYNTHESIS OF COMPOUNDS AND COMBINATORIAL LIBRARIES | ARQULE, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-1998046551-A9 | SYNTHESIS AND USE OF BIASED ARRAYS | — | 1999-03-18 | — | — | WO | disclosed |
| WO-1998046551-A1 | SYNTHESIS AND USE OF BIASED ARRAYS | ARQULE, INC. (US) | 1998-10-22 | — | — | WO | disclosed |
| EP-0386940-A1 | 6-Beta-(alpha-etherified oxymino)-acyl amino penicillins | BEECHAM GROUP PLC (GB) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119991-A1 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | CHRM1, CHRM3, CHRM2 | CES2 337/4885CES1 383/4885CYP11B1 534/4885 |
| US-20050054664-A1 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | CHRM1, CHRM3, CHRM2 | CES2 470/4885CES1 568/4885CYP11B1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.